Estados Unidos - inglês - NLM (National Library of Medicine)

aurobindo pharma limited - perindopril erbumine (unii: 1964x464oj) (perindoprilat - unii:2uv6znq92k) - perindopril erbumine 2 mg - perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ace inhibitor. perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes. [see drug interactions (7.8) ] perindopril erbumine tablets are contraindicated in combination with neprilysin inhibitor (e.g., sacubitril). do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see warnings and precautions (5.1) ]. pregnancy category d [see boxed warning and warnings and precautions (5.4)] .  use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. when pregnancy is detected, discontinue perindopril erbumine as soon as possible. these adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. in the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. perform serial ultrasound examinations to assess the intra-amniotic environment. if oligohydramnios is observed, discontinue perindopril erbumine, unless it is considered lifesaving for the mother. fetal testing may be appropriate, based on the week of pregnancy. patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. closely observe infants with histories of in utero exposure to perindopril erbumine for hypotension, oliguria, and hyperkalemia [see use in specific populations (8.4) ] . radioactivity was detectable in fetuses after administration of 14 c-perindopril to pregnant rats. milk of lactating rats contained radioactivity following administration of 14 c-perindopril. it is not known whether perindopril is secreted in human milk. because many drugs are secreted in human milk, caution should be exercised when perindopril erbumine is given to nursing mothers. neonates with a history of in utero exposure to perindopril erbumine:   if oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. perindopril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of these infants. safety and effectiveness of perindopril erbumine in pediatric patients have not been established. the mean blood pressure effect of perindopril was somewhat smaller in patients over 60 than in younger patients, although the difference was not significant. plasma concentrations of both perindopril and perindoprilat were increased in elderly patients compared to concentrations in younger patients. no adverse effects were clearly increased in older patients with the exception of dizziness and possibly rash. start at a low dose and titrate slowly as needed. monitor for dizziness because of potential for falls. experience with perindopril erbumine in elderly patients at daily doses exceeding 8 mg is limited. dosage adjustment may be necessary in renally impaired patients [see dosage and administration (2.3) and clinical pharmacology (12.3)] . the bioavailability of perindoprilat is increased in patients with impaired hepatic function [see clinical pharmacology (12.3)] .

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; water for injections; sodium; octanoate - indications as at 27 january 2000 : hypovolaemia/shock: preservation of an adequate circulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre), or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be a preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: water for injections; sodium; chloride; octanoate - indications as at 27 january 2000: hypovolaemia/shock: preservation of an adequate circulating blood volume should be the primary aim of therapy. the initital resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre), or it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initital resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 40 g/l - injection, solution - excipient ingredients: chloride; octanoate; water for injections; sodium - indications as at 27 january 2000 :hypovolaemia/shock: preservation of an adequate cirulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as a first-line replacement. albumex 4 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25g/litre) or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 4 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass: albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, aneamia or repeat surgery. for post-operative hypovolaemia albumex 4 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange: albumex 4 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be preferred replacement.,albumex 4 is a plasma volume expander for restoration and maintenance of circulating blood volume. albumex 4 may be used for priming the pump for cardiopulmonary bypass surgery. albumex 4 is indicated as a replacement solution in plasma exchange procedures.

Estados Unidos - inglês - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - perindopril erbumine (unii: 1964x464oj) (perindoprilat - unii:2uv6znq92k) - perindopril erbumine 2 mg - perindopril erbumine is indicated for the treatment of patients with essential hypertension. perindopril erbumine may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. perindopril erbumine is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. perindopril erbumine can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. perindopril erbumine is contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ace inhibitor. perindopril erbumine is also contraindicated in patients with hereditary or idiopathic angioedema. do not co-administer aliskiren with perindopril erbumine in patients with diabetes [see drug interactions (7.8) ]. perindopril erbumine is contraindicated in combination with neprilysin inhibitor (e.g., sacubitril).

Estados Unidos - inglês - NLM (National Library of Medicine)

lupin pharmaceuticals, inc - perindopril erbumine (unii: 1964x464oj) (perindopril - unii:y5gmk36kgy) - perindopril erbumine 2 mg - stable coronary artery disease perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. when using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (see warnings .) in considering use of

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

octapharma limited - albumin human - solution for infusion - 200 g/l

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

octapharma limited - albumin human - solution for infusion - 50 g/l

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - aggregated albumin, quantity: 2.5 mg; stannous chloride dihydrate, quantity: 0.1 mg; sodium chloride, quantity: 1.2 mg; albumin, quantity: 5 mg - powder - excipient ingredients: nitrogen; water for injections - technetium tc 99m albumin aggregated injection is a lung imaging agent which may be used as an adjunct in the evaluation of pulmonary perfusion in adults and paediatric patients. technetium tc 99m albumin aggregated injection may be used in adults as an imaging agent to aid in the evaluation of peritoneovenous (leveen) shunt patency.

Malta - inglês - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 50 g/l - blood substitutes and perfusion solutions